荣昌生物(09995.HK)：泰它西普(商品名：泰爱)治疗IgA肾病中国III期临床研究A阶段达到主要终点

Core Viewpoint - Rongchang Biopharma (09995.HK) announced that its self-developed innovative drug, Tai Aixin (泰爱®), a world-first BLyS/APRIL dual-target fusion protein, has achieved the primary research endpoint in the Phase III clinical study for treating IgA nephropathy (IgAN) in China [1] Summary by Categories - Clinical Development - The Phase III clinical study for Tai Aixin has reached the primary research endpoint [1] - The company plans to submit a New Drug Application (BLA) to the National Medical Products Administration (NMPA) in China as soon as possible [1]